Adjuvant Therapy

ACC overview

Adjuvant therapy in ACC is best organized around who is truly high risk, which postoperative patients are most likely to benefit from mitotane, and where radiotherapy or chemotherapy may add local or systemic control.¹²³

Clinical Map

Postoperative Mitotane in ACC

This cluster focuses on the evidence, monitoring logic, toxicity tradeoffs, and selection questions around adjuvant mitotane after complete resection.¹²³

Grouped note: Postoperative Mitotane in ACC

Adjuvant Radiotherapy and Local Control in ACC

This note groups work on postoperative radiotherapy, margin status, local recurrence risk, and attempts to improve locoregional control after surgery.¹²³

Grouped note: Adjuvant Radiotherapy and Local Control in ACC

How to Read This Literature

The grouped notes below separate postoperative systemic treatment from locoregional intensification and patient-selection work so the literature can be read by decision point rather than by era.¹²³

See Also

• localized_disease_management
• surveillance_after_curative_intent_therapy
• staging_and_prognostic_stratification
• radiotherapy_and_locoregional_oncology

References

Footnotes

1. [Cis-platinum used for the prevention of the recurrence of adrenal cortical carcinoma: report of a case].. Hinyokika Kiyo. 1985. PMID: 4050625. Local full text: 4050625.md ↩ ↩² ↩³ ↩⁴

2. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients.. Cancer. 1995. PMID: 7736405. Local full text: 7736405.md ↩ ↩² ↩³ ↩⁴

3. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer.. Cancer. 1993. PMID: 8490842. Local full text: 8490842.md ↩ ↩² ↩³ ↩⁴